GenomeWebinars
Sponsored by Rancho Biosciences
Harmonizing Disease Phenotypes to Support Genetic Analysis: UK Biobank Clinical Code Curation Challenges and Solutions
The UK Biobank, a rich source of genetic data on half a million people, provides a large collection of clinical data from different healthcare providers and sources resulting in inconsistent medical terminology. To provide a more comprehensive picture of one’s medical history to support genetic and other analyses, clinical data cleaning and standardization are needed.
In this webinar, Sándor Szalma, global head of genetics and systems biology at Takeda Pharmaceuticals, will discuss how, using the UK Biobank Primary Care clinical dataset, Takeda and Rancho Biosciences teams evaluated several approaches to map a subset of Read codes to ICD and SNOMED CT disease terms. Challenges in mapping Read codes were identified. A curation and data integration pipeline for harmonizing diagnoses is proposed and can be used for other biobank and EHR data standardization.
Sponsored by
Sponsored by Scopio Labs
A New Generation of Digital Morphology: How Fully Digital Remote Workflows Accelerate Diagnosis and Improve Patient Care
Complete blood counts requiring morphological examination are a notorious bottleneck in the hematology lab. They are personnel- and expertise-intensive and require time-consuming manual microscopy and workflows.
But what if these workflows were digitized such that manual microscopy was no longer necessary? What would be the impact on lab efficiency and patient care?
Facing slow throughput and ongoing staffing pressures at his lab, Dr. Lukas Graf and his team at the Center for Laboratory Medicine (ZLM) in St. Gallen, Switzerland, asked that question and found an unequivocal answer.
In this webinar, you’ll hear from Dr. Graf, who is head of the Department of Clinical Chemistry, Hematology, and Immunology at ZLM, about their experience adopting digital workflows and remote diagnostic reviews.
Tune in to learn:
- How digital workflows transformed turnaround times and throughput for peripheral blood smear review at ZLM
- The role of full-field technology in the remote diagnostics equation
- How ZLM's staff responded to the dramatic change in workflows and technology at their hub and satellite lab
Sponsored by
Sponsored by Meridian Biosciences
Current Trends in H. pylori Testing: Disease State and Diagnostic Modalities
Sponsored by
Sponsored by Biological Dynamics
Unlocking Insights from Extracellular Vesicles: A Novel Approach to Pancreatic Cancer Detection
|
Using a blood test to differentiate patients with pancreatic cancer (pancreatic ductal adenocarcinoma, or PDAC) from patients with precancerous intraductal papillary mucinous neoplasms (IPMN) and pancreatitis is a challenge using traditional blood biomarkers like CA 19-9. A potentially valuable source of cancer-derived biomarkers is carried by extracellular vesicle (EV) nanoparticles released by tumors into circulation throughout their development, including actively secreted extracellular vesicles, organelle fragments, and cell-free DNA (cf-DNA) nanoparticles. Each of these nanoparticle types carry important cancer-related biomarkers but are not currently used for clinical diagnostic applications due the time-consuming recovery methods available. In this webinar, Stuart Ibsen of Oregon Health and Science University will discuss the use of high conductance dielectrophoresis to simultaneously recover different nanoparticle types from a single undiluted plasma sample in a quick and easy microfluidic chip format. This method uses dielectric property differences between the nanoparticles and the surrounding plasma to create a force that pulls nanoparticles down to an electrode array, allowing a wash to remove the bulk plasma. Ibsen and colleagues used this method to simultaneously collect both EVs and cf-DNA nanoparticles showing colocalization around the edges of the electrodes used to generate the DEP force. In his talk, Ibsen will demonstrate that the combination of EV biomarkers (Glypican-1) and the level of cf-DNA nanoparticles can be used to successfully differentiate PDAC patients from patients with IPMN, which is clinically important because IPMNs are a major source of false positives for multiomic biology-based screening. |
Sponsored by
